Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Black Diamond Therapeutics (BDTX) Liabilities and Shareholders Equity: 2018-2020

Historic Liabilities and Shareholders Equity for Black Diamond Therapeutics (BDTX) over the last 3 years, with Dec 2020 value amounting to $329.7 million.

  • Black Diamond Therapeutics' Liabilities and Shareholders Equity fell 20.87% to $274.1 million in Q3 2021 from the same period last year, while for Sep 2021 it was $1.2 billion, marking a year-over-year decrease of 0.99%. This contributed to the annual value of $329.7 million for FY2020, which is 108.26% up from last year.
  • Per Black Diamond Therapeutics' latest filing, its Liabilities and Shareholders Equity stood at $329.7 million for FY2020, which was up 108.26% from $158.3 million recorded in FY2019.
  • Black Diamond Therapeutics' 5-year Liabilities and Shareholders Equity high stood at $329.7 million for FY2020, and its period low was $51.8 million during FY2018.
  • Over the past 3 years, Black Diamond Therapeutics' median Liabilities and Shareholders Equity value was $158.3 million (recorded in 2019), while the average stood at $179.9 million.
  • Data for Black Diamond Therapeutics' Liabilities and Shareholders Equity shows a peak YoY soared of 205.44% (in 2019) over the last 5 years.
  • Yearly analysis of 3 years shows Black Diamond Therapeutics' Liabilities and Shareholders Equity stood at $51.8 million in 2018, then skyrocketed by 205.44% to $158.3 million in 2019, then skyrocketed by 108.26% to $329.7 million in 2020.